Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 16/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7809558 | 0.90 | MAPT (0.67) | MAPTPKMMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL975415 | 0.88 | MAPT (0.59) | MAPTMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL21753620 | 0.86 | MAPT (0.61) | MAPTMAPK1ALDH1A1NPSR1 | |
| SCHEMBL16262970 | 0.84 | MAPT (0.51) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL16262967 | 0.84 | MAPT (0.51) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL21588984 | 0.84 | MAPT (0.55) | MAPTPKMMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL19633486 | 0.82 | KMT2A (0.50) | MAPTPKMMAPK1MEN1KMT2A | |
| SCHEMBL1631388 | 0.81 | MAPT (0.56) | MAPTPKMMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL19633305 | 0.81 | MAPT (0.54) | MAPTMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL19633404 | 0.80 | MAPT (0.53) | MAPTPKMMAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108264511-B | Heterocyclic derivative, preparation method thereof and application thereof in medicine | 浙江海正药业股份有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-20070254894-A1 | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation | KANE JOHN L JR | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254894-A1 | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation | MKI67, VEGFA, KDR | MAPT 4441/4885PKM 3630/4885MAPK1 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.